Semaglutide Frequently Asked Questions

Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1) with structural modifications that extend its half-life to approximately one week. It is a 31-amino acid peptide with a C18 fatty acid chain that promotes albumin binding, slowing clearance from the body. Peptides Pharma Semaglutide is formulated at >99% purity in a lyophilized vial.

Semaglutide binds to and activates the GLP-1 receptor, which is expressed in the pancreas, brain, gastrointestinal tract, and cardiovascular system. This activation promotes insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on hypothalamic appetite centres to reduce food intake. The fatty acid modification enables albumin binding, extending its circulating half-life. These findings are from extensive published clinical research.

Semaglutide is studied in research related to weight management, type 2 diabetes models, appetite regulation, cardiovascular outcomes, non-alcoholic steatohepatitis (NASH), and neurodegenerative disease models. It has been the subject of the SUSTAIN, PIONEER, and STEP clinical trial programmes.

Peptides Pharma Semaglutide is manufactured to >99% purity in GMP-certified, ISO 7 cleanroom facilities. Each batch undergoes rigorous third-party HPLC and mass spectrometry verification. Certificates of Analysis are available for every production batch.

Lyophilized Semaglutide should be stored at 2-8°C, protected from light. Do not freeze. Once reconstituted, keep refrigerated at 2-8°C and use within 28 days. Semaglutide's peptide structure is sensitive to temperature extremes, so proper cold-chain storage is essential.

Reconstitute Semaglutide by slowly injecting bacteriostatic water along the inside wall of the vial. Allow the powder to dissolve gently without shaking or vortexing. The volume of bacteriostatic water used will determine the concentration of the final solution for dosing calculations.

Reconstituted Semaglutide stored at 2-8°C with bacteriostatic water is typically stable for up to 28 days. Always use aseptic technique when drawing from the vial. Semaglutide's extended half-life means fewer injections per research cycle, reducing contamination risk from vial access.

Yes. Peptides Pharma Semaglutide is supplied strictly for laboratory and research use. While Semaglutide is an approved prescription medicine under certain brand names, Peptides Pharma's formulation is sold exclusively as a research compound and is not intended for self-administration or therapeutic use.

Published clinical trials have employed dose-escalation protocols for Semaglutide, typically starting at lower doses and increasing gradually. Researchers should consult peer-reviewed literature, particularly the STEP and SUSTAIN trial publications, for detailed dosing parameters relevant to their research objectives. Peptides Pharma does not provide individualised dosing recommendations.

Semaglutide is a single GLP-1 receptor agonist, while Tirzepatide acts on both GIP and GLP-1 receptors (dual agonist). Both are studied for metabolic research but work through different receptor mechanisms. The choice between them depends on the specific research question — single-pathway vs. dual-pathway activation in metabolic models.